A recent University College London research estimates that 1.6 million adults in England, Wales and Scotland used GLP-1s, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight.
Injectable formulations, by contrast, are described as allowing more precise control and easier titration in smaller increments, which the article says may ease the nausea profile during the initial weeks of treatment
KD is characterized by a dietary pattern that predominates in fats, has a minimal amount of carbohydrates, and a moderate intake of protein
When investigating taste disturbances, it is also worth considering other potential causes, including concurrent medications, underlying health conditions, or nutritional deficiencies (such as zinc or vitamin B12 deficiency)
Affordable & Transparent Pricing No hidden fees GLP-1 Semaglutide costs $275 $150* per month (4 weekly injectionsjust $37.5 per injection)
is the major contributor to the North America GLP-1 targeted peptide weight loss drugs market, driven by its large population affected by obesity and metabolic diseases